Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds

Patent metadata

Field	Value
Publication number	US-10286065-B2
Application number	US-201514860205-A
Country	US
Kind code	B2
Filing date	Sep 21, 2015
Priority date	Sep 19, 2014
Publication date	May 14, 2019
Grant date	May 14, 2019

Abstract

Embodiments are directed to compositions and methods for treating viral infections.

First claim

The invention claimed is:

1. A composition comprising: a co-formulation of (a) PAM2CSK4, (b) type C CpG oligodeoxynucleotide TLR 9 agonist, and (c) antiviral pharmaceutical selected from oseltamivir and ribavirin, wherein the composition is formulated for administration to the lungs by nebulization or aerosolization.

2. The composition of claim 1 , wherein the type C CpG oligodeoxynucleotide is ODN2395 or ODNM362 or ODN10101.

3. A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of the composition of claim 1 to an individual that has or is at risk of viral infection.

4. The method of claim 3 , wherein the subject has been exposed to a virus.

5. The method of claim 3 , wherein the virus is a Adenoviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Orthomyxoviridae, Paramyxovirinae, Pneumovirinae, Picomaviridae, Poxyiridae, Retroviridae, or Togaviridae.

6. The method of claim 3 , wherein the virus is Parainfluenza, Influenza, H5N1, Marburg, Ebola, Severe acute respiratory syndrome coronavirus (SARS-COV), Middle eastern respiratory syndrome coronavirus (MERS-COV), yellow fever virus, human respiratory syncytial, Hantavirus, or Vaccinia virus.

7. The method of claim 3 , wherein the composition is administered by nebulization.

8. The method of claim 3 , wherein the lipopeptide, immune stimulatory oligonucleotide and anti-viral drug are administered in an amount of from about 0.1 mg/kg to about 100 mg/kg of the individual's body weight.

9. A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of a composition comprising in an aerosolized formulation: (a) PAM2CSK4, (b) type C CpG oligodeoxynucleotide TLR9 agonist, and (c) antiviral pharmaceutical selected from oseltamivir and ribavirin, to an individual that has or is at risk of viral infection.

10. The method of claim 9 , wherein the type C oligodeoxynucleotide TLR9 agonist is ODN2395 or ODNM362 or ODN 10101.

11. A nebulizer comprising (a) PAM2CSK4, (b) type C CpG oligodeoxynucleotide TLR9 agonist, and (c) anti-viral pharmaceutical selected from oseltamivir and ribavirin.

Assignees

• Univ Texas
• Pulmotect Inc
• Baylor College Medicine

Inventors

• Dickey Burton
• Evans Scott
• Gilbert Brian
• Markesich Diane
• Scott Brenton
• Tuvim Michael

Classifications

• A61P31/12

  Antivirals · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/0078

  for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions · CPC title

• A61K38/06

  Tripeptides · CPC title

• A61K31/24

  having an amino or nitro group · CPC title